NCT03498196 - A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions

Bladder CancerMetastatic Bladder CancerInvasive Bladder Cancer

Interventions

DRUG

Avelumab

avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.

Trial Locations (3)

Baylor College of Medicine Medical Center - McNair Campus, Houston

Ben Taub General Hospital, Houston

Michael E. DeBakey Veteran Affairs Medical Center, Houston